IP Library Granted Patent US 9,320,890
Granted Patent B2
US 9,320,890 · App. 12/941,839 · Granted Apr 26, 2016

Drug eluting composite

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,320,890
App. No.
12/941,839
Granted
Apr 26, 2016
Kind
B2
Abstract

The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.

Claims (42)

1. A therapeutic-releasing material disposed on a substrate comprising:

a first biocompatible polymeric material having a therapeutic agent incorporated in at least a portion thereof and adjacent the substrate;

a second biocompatible polymeric material having a first surface and a second surface, wherein the first biocompatible polymeric material is incorporated into at least a portion of said first surface;

an impermeable capping layer surrounding at least a portion of an outer surface of the first biocompatible material;

a biocompatible polymeric barrier disposed within said first biocompatible polymeric material and having a height such that said barrier extends a full vertical distance between the impermeable capping layer and the substrate,

wherein said barrier is substantially impermeable to said therapeutic agent;

at least one formed opening having a dimension and a location and extending through the impermeable capping layer; and

said barrier is structured with a length such that said barrier extends from a first edge of the first biocompatible polymeric material towards a second edge of the first biocompatible polymeric material, and ends a predetermined distance away from the second edge.

2. The therapeutic-releasing material of claim 1 further comprising a plurality of formed openings in said impermeable capping layer, wherein the therapeutic agent release rate is at least partially determined by at least one of a dimensions, location, and number of said plurality of formed openings.

3. The therapeutic-releasing material of claim 1 wherein said second biocompatible polymeric material comprises a fluoropolymer composition.

4. The therapeutic-releasing material of claim 3 wherein said fluoropolymer is porous polytetrafluoroethylene.

5. The therapeutic-releasing material of claim 1 wherein said biocompatible polymeric barrier is a silicone composition.

6. The therapeutic-releasing material of claim 1 wherein said therapeutic agent is dexamethasone sodium phosphate.

7. The therapeutic-releasing material of claim 1 wherein said therapeutic agent release rate is further determined by said first biocompatible polymeric material.

8. The therapeutic-releasing material of claim 1 wherein said second biocompatible polymeric material is a film.

9. The therapeutic-releasing material of claim 1 wherein said substrate is at least a portion of a cardiac pacing lead.

10. The therapeutic-releasing material of claim 1 wherein said therapeutic-releasing material is wrapped at least once around said substrate material.

11. The therapeutic-releasing material of claim 10 wherein said wrapped therapeutic-releasing material has a spiral configuration.

12. The therapeutic-releasing material of claim 1 wherein said substrate is at least a portion of a cardiac pacing lead.

13. A cardiac pacing lead comprising:

a cardiac pacing lead element having a proximal end and a distal end;

an electrically conductive connector at said proximal end;

an electrode located at said distal end;

at least one electrically conductive element connecting said connector to said electrode; and

at least a portion of said cardiac pacing lead element covered with a therapeutic-releasing material comprising:

a first biocompatible polymeric material having a therapeutic agent incorporated in at least a portion thereof and adjacent the cardiac pacing lead element;

a second biocompatible polymeric material having a first surface and a second surface, wherein the first biocompatible polymeric material is incorporated into at least a portion of said first surface;

an impermeable capping layer surrounding at least a portion of an outer surface of the first biocompatible material and having at least one formed opening having a dimension and a location and extending through impermeable capping layer; and

a plurality of biocompatible polymeric barriers disposed within said first biocompatible polymeric material and having a height such that each of said plurality of biocompatible polymeric barriers extends a full vertical distance between an inner surface and the outer surface of the first biocompatible material,

wherein said plurality of biocompatible barriers are substantially impermeable to said therapeutic agent; and

each of said plurality of biocompatible polymeric barriers is positioned parallel to a longitudinal center line of the therapeutic-releasing material, and each of said plurality of biocompatible polymeric barriers has a length such that each of said plurality of biocompatible polymeric barriers extends from a first edge of the first biocompatible polymeric material towards a second edge of the first biocompatible polymeric material, and ends a predetermined distance away from the second edge.

14. The cardiac pacing lead of claim 13 wherein the therapeutic agent release rate is at least partially determined by at least one of the dimension and location of said at least one formed opening.

15. The cardiac pacing lead of claim 13 wherein said second biocompatible polymeric material comprises a fluoropolymer composition.

16. The cardiac pacing lead of claim 15 wherein said fluoropolymer is porous polytetrafluoroethylene.

17. The cardiac pacing lead of claim 13 wherein said plurality of biocompatible polymeric barriers are a silicone composition.

18. The cardiac pacing lead of claim 13 wherein said therapeutic agent is dexamethasone sodium phosphate.

19. The cardiac pacing lead of claim 13 further comprising a plurality of formed openings in said impermeable capping layer, wherein the therapeutic agent release rate is at least partially determined by at least one of the dimensions, location, and number of said plurality of formed openings.

20. A therapeutic releasing material comprising

a first biocompatible polymeric material having a surface and having a therapeutic agent disposed on the surface, wherein an elution pathway extends along at least a section of the surface;

an impermeable capping layer covering all of said first biocompatible material except for a location of an opening extending through the impermeable capping layer and in communication with said elution pathway; and

a biocompatible polymeric barrier disposed within said first biocompatible polymeric material and having a height such that said barrier extends a full vertical distance between the impermeable capping layer covering an inner surface of the first biocompatible material and the impermeable capping layer covering an outer surface of the first biocompatible material.

21. The therapeutic-releasing material of claim 20 , wherein a therapeutic agent release rate is at least partially determined by at least one of dimension and location of said opening.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2012
From: GORE ENTERPRISE HOLDINGS, INC.
To: W. L. GORE & ASSOCIATES, INC.
Reel/Frame 027906/0508 →